(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release
Posted in Berlin, Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Technology
Tagged Boston Radionuclide Theranostics Forum, clinical development, Dr. Harald Hasselmann, Eckert & Ziegler, German American Business Council, Industry innovation, Morrison Foerster, nuclear medicine, patient access, precision oncology, radionuclide theranostics, radiopharmaceutical community, radiopharmaceuticals, radiotherapy, Solomon Partners
(IN BRIEF) The University of Glasgow is leading the innovative FOxTROT 5 trial, which is offering elderly colon cancer patients the opportunity to participate in a groundbreaking immunotherapy study. The trial will administer dostarlimab before surgery, targeting a specific type … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer research, cancer treatment, chemotherapy, clinical trial, clinical trial protocol, colon cancer, deficient mismatch repair, dMMR, dostarlimab, Elderly Patients, FOxTROT 5, frail patients, GSK, immunotherapy, partnership, precision oncology, surgery, UK hospitals, University of Birmingham, University of Glasgow, University of Leeds
Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged Bayer, CDK2, CDK2 inhibitors, Cedilla, Cedilla Therapeutics, Cyclin Dependent Kinase 2, cyclin E, CyclinE1, CyclinE1/CDK2 complex inhibitors, Dominik Ruettinger, Exclusive license agreement, M.D., Neil Exter, oncogenic drivers, Ph.D., precision oncology
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?